Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble

Argenx said on Thursday it had discontinued a late-stage study of its efgartigimod ​drug in adults with Sjögren's disease, ‌an autoimmune condition that damages the glands producing tears and saliva, ...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。